HEMC

Hemcheck SwedenOM:HEMC Stock Report

Market Cap

kr42.6m

7D

-4.7%

1Y

-23.8%

Updated

17 Sep, 2021

Data

Company Financials
HEMC fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

HEMC Overview

Hemcheck Sweden AB (publ) operates as a medical technology company in Sweden.

Price History & Performance

Summary of all time highs, changes and price drops for Hemcheck Sweden
Historical stock prices
Current Share Pricekr2.21
52 Week Highkr2.00
52 Week Lowkr6.46
Beta0.58
1 Month Change-28.94%
3 Month Change-25.34%
1 Year Change-23.79%
3 Year Change-82.68%
5 Year Changen/a
Change since IPO-63.47%

Recent News & Updates

Jan 03
Need To Know: Hemcheck Sweden AB (publ) (STO:HEMC) Insiders Have Been Buying Shares

Need To Know: Hemcheck Sweden AB (publ) (STO:HEMC) Insiders Have Been Buying Shares

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...

Jan 03
Insider Buying: The Hemcheck Sweden AB (publ) (STO:HEMC) Director Just Bought 36% More Shares

Insider Buying: The Hemcheck Sweden AB (publ) (STO:HEMC) Director Just Bought 36% More Shares

Even if it's not a huge purchase, we think it was good to see that Hjalmar Didrikson, the Director of Hemcheck Sweden...

Shareholder Returns

HEMCSE Medical EquipmentSE Market
7D-4.7%-2.0%-1.2%
1Y-23.8%47.6%33.3%

Return vs Industry: HEMC underperformed the Swedish Medical Equipment industry which returned 47.3% over the past year.

Return vs Market: HEMC underperformed the Swedish Market which returned 34.6% over the past year.

Price Volatility

Is HEMC's price volatile compared to industry and market?
HEMC volatility
HEMC Beta0.58
Industry Beta0.77
Market Beta1

Stable Share Price: HEMC is more volatile than 75% of Swedish stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: HEMC's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Swedish stocks.

About the Company

FoundedEmployeesCEOWebsite
20105Joen Averstadhttps://www.hemcheck.com

Hemcheck Sweden AB (publ) operates as a medical technology company in Sweden. The company develops and commercializes Helge, which detects hemolysis in blood samples at the point of care. It serves emergency departments in the European Union and the United States.

Hemcheck Sweden Fundamentals Summary

How do Hemcheck Sweden's earnings and revenue compare to its market cap?
HEMC fundamental statistics
Market Capkr42.63m
Earnings (TTM)-kr13.14m
Revenue (TTM)kr3.06m

13.9x

P/S Ratio

-3.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
HEMC income statement (TTM)
Revenuekr3.06m
Cost of Revenuekr513.94k
Gross Profitkr2.55m
Expenseskr15.69m
Earnings-kr13.14m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.76
Gross Margin83.22%
Net Profit Margin-429.10%
Debt/Equity Ratio0.0%

How did HEMC perform over the long term?

See historical performance and comparison

Valuation

Is Hemcheck Sweden undervalued compared to its fair value and its price relative to the market?

1.06x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate HEMC's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate HEMC's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: HEMC is unprofitable, so we can't compare its PE Ratio to the Swedish Medical Equipment industry average.

PE vs Market: HEMC is unprofitable, so we can't compare its PE Ratio to the Swedish market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate HEMC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: HEMC is good value based on its PB Ratio (1.1x) compared to the SE Medical Equipment industry average (5.2x).


Future Growth

How is Hemcheck Sweden forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

20.9%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Hemcheck Sweden has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Hemcheck Sweden performed over the past 5 years?

-28.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: HEMC is currently unprofitable.

Growing Profit Margin: HEMC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: HEMC is unprofitable, and losses have increased over the past 5 years at a rate of 28.6% per year.

Accelerating Growth: Unable to compare HEMC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: HEMC is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (14.9%).


Return on Equity

High ROE: HEMC has a negative Return on Equity (-32.82%), as it is currently unprofitable.


Financial Health

How is Hemcheck Sweden's financial position?


Financial Position Analysis

Short Term Liabilities: HEMC's short term assets (SEK16.3M) exceed its short term liabilities (SEK2.3M).

Long Term Liabilities: HEMC has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: HEMC is debt free.

Reducing Debt: HEMC has no debt compared to 5 years ago when its debt to equity ratio was 65.3%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: HEMC has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: HEMC has less than a year of cash runway if free cash flow continues to reduce at historical rates of 14.4% each year


Dividend

What is Hemcheck Sweden current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate HEMC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate HEMC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if HEMC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HEMC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of HEMC's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.0yrs

Average management tenure


CEO

Joen Averstad (37 yo)

2.33yrs

Tenure

Mr. Joen Averstad serves as the Chief Executive Officer at Hemcheck Sweden AB (publ) since May 2019. He serves as a Board Member of AIK Fotboll AB.


Leadership Team

Experienced Management: HEMC's management team is considered experienced (3 years average tenure).


Board Members

Experienced Board: HEMC's board of directors are considered experienced (5.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 22.8%.


Top Shareholders

Company Information

Hemcheck Sweden AB (publ)'s employee growth, exchange listings and data sources


Key Information

  • Name: Hemcheck Sweden AB (publ)
  • Ticker: HEMC
  • Exchange: OM
  • Founded: 2010
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: kr42.627m
  • Shares outstanding: 19.29m
  • Website: https://www.hemcheck.com

Number of Employees


Location

  • Hemcheck Sweden AB (publ)
  • Karlstads universitet
  • Biomedicin
  • Karlstad
  • Värmland County
  • 651 88
  • Sweden

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/17 22:31
End of Day Share Price2021/09/17 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.